.jpg?format=webp&width=780)
Coronavirus disease 2019 (COVID-19) is often accompanied by secondary infections, such as invasive aspergillosis. This study evaluated risk factors for developing COVID-19-associated pulmonary aspergillosis (CAPA) and their clinical outcomes. This multicenter retrospective cohort study included critically ill COVID-19 patients from July 2020 through March 2021. Among 187 eligible patients, 17 (9.1%) developed CAPA, which is equal to 33.10 per 10,000 patient-days. The study showed that the dose of corticosteroid use might be a risk factor for CAPA development and the possibility of CAPA contributing to adverse outcomes in critically ill COVID-19 patients.
Like
Save
Share